Short answer
Amgen (AMGN) filed its Q1 2026 10-Q quarterly report on May 1, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $8.6B (up 5.8% year over year) with net income of $1.8B.
Q1 2026 key financials · XBRL
- Revenue
- $8.6B
- +5.8% YoY
- Net income
- $1.8B
- +5.1% YoY
- Operating margin
- 30.9%
- EPS (diluted)
- $3.34
- +4.4% YoY
Source: XBRL data from the Amgen (AMGN) Q1 2026 10-Q on SEC EDGAR. USD.
Amgen Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Total revenue $8.618B, up 6% YoY from $8.149B
- Operating income $2.666B vs $1.178B; operating expense $5.952B vs $6.971B
- Product sales $8.218B, up 4%; ROW sales $2.445B, up 11%, best geography
- Operating cash flow, cash position, and capital deployment figures not provided
- Near-term headwinds: IRA pricing, 340B expansion, tariffs, geopolitical volatility, and TAVNEOS regulatory uncertainty
Risk Factors
- New regulatory risk: October 2025 Section 301 investigation into China trade-agreement implementation could produce additional tariffs
- Most materially updated market risk: Middle East conflict increased energy, transportation, shipping, travel, security, and cybersecurity volatility
- Biosimilar competition risk: Delayed approvals or loss of first-to-market positions could materially reduce future biosimilar sales
- Financial-market risk: Majority of cash held above insured limits at multinational financial institutions
- Investment risk: Capital-market volatility could trigger impairments or losses on Amgen’s significant investment portfolio
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Amgen quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.